retatrutide availability clinical trial UK: 2026 & Approval Guide – Trim Lilly's triple agonist achieves 16.8%

Hypoglycemia: This is when blood sugar drops too low, and can happen if youre already taking a medication to control blood sugar

Each profile identifies its stated source and evidence tier

16, 2016 /CNW/ - Eli Lilly Canada announced the approval of Trulicity (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes to improve glycemic control

While again showing significant improvement in OFF- and ON-time outcomes when switching from placebo to open-label opicapone treatment those initiated on opicapone at open-label start did not have the same degree of improvement as those with opicapone treatment at start of the double-blind period with a group difference in OFF- and ON-time of 30 (p = 0.2) and 44 min (p = 0.05) at end of open-label week 52 despite similar levodopa equivalent daily dosage in both groups